Jazz Pharmaceuticals plc, of Dublin, said the initial purchasers of its private offering of $500 million aggregate principal amount of 1.5 percent exchangeable senior notes due 2024 by Jazz Investments I Ltd., its wholly owned subsidiary, have exercised in full their option to purchase an additional $75 million aggregate principal amount of notes.